Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead

Willers, Henning; Krause, Mechthild; Faivre-Finn, Corinne; Chalmers, Anthony J.

doi:10.1016/j.ijrobp.2021.10.142

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMZ is a DNA methylating agent that is used worldwide as the standard-of-care chemotherapeutic against newly diagnosed glioblastoma, including to treat residual invasive-edge cancer cells left behind following surgical resection [ 34 ]. More recently, the PARP1 inhibitor (PARPi) Olaparib/Lynparza has been incorporated into treatment regimens for breast, prostate and ovarian cancer, including strategies delivering chemoradiosensitisation of BRCA-deficient tumours, and is currently undergoing clinical trial assessment for glioblastoma [ 35 , 36 , 37 , 38 ]. The use of TMZ and PARPi in cancer treatment therefore provides a strong preclinical rationale to test their combined efficacy with TTFields-mediated downregulation of FA/BRCA proteins [ 31 , 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity

Jones,

Vanderlinden,

Rominiyi

et al. 2024

Cancers

View full text Add to dashboard Cite

Glioblastoma is an aggressive, incurable brain cancer with poor five-year survival rates of around 13% despite multimodal treatment with surgery, DNA-damaging chemoradiotherapy and the recent addition of Tumour Treating Fields (TTFields). As such, there is an urgent need to improve our current understanding of cellular responses to TTFields using more clinically and surgically relevant models, which reflect the profound spatial heterogeneity within glioblastoma, and leverage these biological insights to inform the rational design of more effective therapeutic strategies incorporating TTFields. We have recently reported the use of preclinical TTFields using the inovitroTM system within 2D glioma stem-like cell (GSC) models and demonstrated significant cytotoxicity enhancement when co-applied with a range of therapeutically approved and preclinical DNA damage response inhibitors (DDRi) and chemoradiotherapy. Here we report the development and optimisation of preclinical TTFields delivery within more clinically relevant 3D scaffold-based primary GSC models of spatial heterogeneity, and highlight some initial enhancement of TTFields potency with temozolomide and clinically approved PARP inhibitors (PARPi). These studies, therefore, represent an important platform for further preclinical assessment of TTFields-based therapeutic strategies within clinically relevant 3D GSC models, aimed towards accelerating clinical trial implementation and the ultimate goal of improving the persistently dire survival rates for these patients.

show abstract